DRG Market Assessment reports

Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…

The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; more than 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

*Key drugs covered: *Admelog / Insulin Lispro Sanofi, Aranesp, Avastin, Basaglar / Abasaglar, Enbrel, Herceptin, Herzuma, Hulio, Humalog, Humira,Inflectra, Kanjinti, Neulasta, Neupogen, Nivestim /…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dementia patient populations, covering 171 countries and more than…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence of…

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta, AstraZeneca’s Saphnelo and…

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…

Fibromyalgia is a chronic condition characterized by pain, tenderness throughout the body, fatigue, and disrupted sleep. Most diagnosed fibromyalgia patients receive prescription drug treatment…

The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest…

The treatment of nonalcoholic steatohepatitis (NASH) (also known as metabolic dysfunction–associated steatohepatitis [MASH]) has enormous potential for growth owing to the prevalence of the…